Iambic Targets $135 Million IPO, Extending 2026 Biotech Listing Momentum
The Catalyst Brief
Coverage
AI in Drug Discovery
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Latest
Xaira Reveals XA-1 And XA-4, Framing X-Design As A Drug-Ready Antibody Engine
The Catalyst Brief
Deep Learning Perturbation Models Beat Uninformative Baselines Under Calibrated Metrics, Nature Study Finds
The Catalyst Brief
Genentech Pays $55 Million Upfront In Earendil Bispecific Deal, Extending Roche’s Oncology Search
The Catalyst Brief
Most read
AI-Centric Biotechs Draw Billion-Dollar Backing, Pressuring Biopharma To Move Risk Checks Upstream
The Catalyst Brief
Biopharma R&D Needs 'Structural Redesign' to Maximize AI Impact, Says McKinsey
The Catalyst Brief
Generate Biomedicines’ GB-0895 Posters Leak Two Weeks Early, Exposing New Phase 1 COPD And Asthma Data
The Catalyst Brief
Insilico Medicine and Lilly Forge $2.75 Billion AI-Driven Drug Commercialization Alliance
The Catalyst Brief
More in this beat
Sep 25, 2026Basecamp Research Raises $140 Million Series C, Extending Investor Appetite For AI-Designed Drug Platforms
The London- and Boston-based company said the oversubscribed round was led by S32 and included NVIDIA, Anthropic and senior biopharma leaders including Roche Vice Chairman André Hoffmann. Basecamp plans to use the financing to move investigational medicines forward, initially focusing on in vivo cell therapies.
The Catalyst Brief
Sep 24, 2026Boehringer Ingelheim Expands Variant Bio Pact Beyond Kidney Disease, Adding More Than $250M In Cardiovascular Economics
The companies are pairing Variant Bio's genomics and multiomic discovery platform with Boehringer's cardiovascular and kidney disease expertise. The commercial signal is that pharmas are continuing to spend on genetically supported target discovery in large chronic diseases, where better target validation can matter more than novelty alone.
The Catalyst Brief
Sep 22, 2026Boehringer Ingelheim Signs Potential $1 Billion Envisagenics Oncology Pact, Expanding RNA-Splicing Target Hunt
Boehringer Ingelheim is betting that alternative RNA splicing can open a less crowded oncology target space, while Envisagenics is using the economics of platform partnering to fund its internal pipeline. The structure shows how AI target-discovery companies are increasingly trying to convert discovery collaborations into financing for wholly owned programs.
The Catalyst Brief
Sep 22, 2026Deep Dive: AI Becomes Core Biopharma Infrastructure, From Pfizer Integration To TechBio Funding
Pharma executives are increasingly describing AI as a structural capability rather than an experimental add-on. At the same time, companies built around machine learning platforms are drawing large partnerships and financing rounds, creating a clearer commercial divide between established use cases and earlier-stage platform promise.
The Catalyst Brief
Sep 9, 2026Forus Secures $150 Million Series C At $3 Billion Valuation, Expanding AI Medication Access Network
Formerly known as Tandem, Forus connects doctors, pharmacies, payers and biopharma and uses AI agents to navigate insurance, financial assistance and pharmacy logistics for prescribed medicines. The new financing will fund more AI agents and clinical models, broader specialty coverage and expansion of the company’s technical and go-to-market teams.
The Catalyst Brief
Aug 27, 2026Generate Biomedicines’ GB-0895 Posters Leak Two Weeks Early, Exposing New Phase 1 COPD And Asthma Data
According to an SEC filing, draft copies of three posters were made publicly available via the ERS website on Aug. 25, nearly two weeks before the Sept. 7 embargo expired. The episode gave investors an early look at ongoing clinical data for golukibart, two days before a scheduled lock-up expiry reshaped the share register.
The Catalyst Brief
Aug 27, 2026Flagship’s ProFound Signs Up To $35 Million Gates Foundation Pact For Preeclampsia Targets
Flagship Pioneering’s ProFound Therapeutics has partnered with the Gates Foundation in a pact worth up to $35 million focused on preeclampsia, a high-blood-pressure disease of pregnancy that can be fatal for mother or child if not addressed. The collaboration pairs ProFound’s proteomics repository with an agentic AI tool meant to help assign function to newly identified targets before laboratory validation.
The Catalyst Brief
Aug 18, 2026Autolomous CEO Argues AI Must Link Shared Failure Data In Cell And Gene Therapy, After Sarepta Safety Setback
The article frames cell and gene therapy as an ecosystem problem rather than a component problem, arguing that isolated work on vectors or gene-editing tools misses the bigger constraint. Its central claim is that AI’s value lies in processing and connecting live operational data across the therapy lifecycle, provided companies share more non-IP information about what fails.
The Catalyst Brief
Aug 12, 2026AI-Centric Biotechs Draw Billion-Dollar Backing, Pressuring Biopharma To Move Risk Checks Upstream
Investor enthusiasm for companies such as Isomorphic Labs, Generate:Biomedicines and NewLimit is pushing biopharma to take machine learning more seriously across discovery and development. The clearest industry implication in the reporting is a shift from treating AI as a productivity tool to treating it as a way to identify failure earlier and allocate capital more selectively.
The Catalyst Brief
Aug 5, 2026QuantHealth Secures $45M to Revolutionize Clinical Trial Simulation With AI
In a notable stride for AI-driven health technology, QuantHealth has secured $45 million in Series B funding to further develop its simulation platform for clinical trials. By offering pharmaceutical companies predictive insights before real-world patient enrollment, QuantHealth is positioning itself as a solution to pervasive challenges within clinical development, such as elevated trial failure rates and sluggish time-to-market for new therapeutics.
The Catalyst Brief
Aug 1, 2026Grove AI’s Rapid Rise: From Startup to Acquisition, Transforming Clinical Trials with Voice Technology
The healthcare industry witnessed one of its fastest success stories as Grove AI, a startup focused on AI-powered voice agents for clinical trial recruitment, was acquired by Hippocratic AI just two years after its founding. This deep dive profiles the technology, strategy, and market forces that shaped Grove AI’s journey and examines the broader implications for digital health innovation.
The Catalyst Brief
Jul 22, 2026AI Data Becomes Sticking Point in Biopharma Dealmaking
The rapid expansion of AI-driven drug discovery is accelerating the complexity of biopharma collaborations. As these partnerships multiply, legal and operational disputes related to data ownership and provenance are surfacing as central friction points, forcing both sides to reconsider deal structures and the future of therapeutic innovation.
The Catalyst Brief
Other beats
Biopharmaceutical Industry
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Biotech Innovation
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Healthcare Investment
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Medical Technology
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Regulatory & Policy
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.